Debora Basile

[Oncoinfo @Oncoinfo_it]

#Bridge23 | #aBCC: quando è indicato passare all’IO di 2L?
Il punto di Maria Grazie Vitale

@PAscierto #sonidegib #carcinomabasocellulare #inibitoridihedgehog

[Arndt Vogel @ArndtVogel]

Treatment of gastric adenocarcinoma: A rapidly evolving landscape
European Journal of Cancer
https://t.co/COTOODaR24
👏Excellent summary
👉Many evolving opportunities - multimodal treatmenet
👉IO + targeted therapies in advanced setting
👉Multiple biopsies at diagnosis are key...
@myESMO

[Arndt Vogel @ArndtVogel]

🔥Sotorasib plus panitumumab vs SOC for mKRASG12C mCRC #ESMO23
✅ CodeBreak 300 phase III
👉960 vs 240 vs plc
👉ORR 26.4 vs 5.7 vs 0
👉DCR 71.7 vs 67.9 vs 46.3
👉mPFS 5.6 vs 3.9 vs 2.2
👉OS: hmm…
🧐met 1° EP, definitely an option, but maybe earlier & w/ CTx
@myESMO

[Arndt Vogel @ArndtVogel]

🔥Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients #ESMO23
✅PEGASUS phs-II, 135 pts
👉Post-OP ctDNA: 35/135 pts (26)
👉ctDNA+ w/ increased risk of relapse, HR 4.37
👉Seroconversion in 40% of LB+
👉Promising benefit for LB guided treatment
@myESMO

[Arndt Vogel @ArndtVogel]

🔥Nab-paclitaxel + gemcitabine vs mFOLFIRINOX vs S-IROX in #PDAC #ESMO23
✅GENERATE 🇯🇵 phs-II/II, 527 pts
👉ORR 35 vs 32 vs 42
👉mOS 17 vs 14 vs 13.6 mo
👉mPFS 6.7 vs 5.8 vs 6.7
👉 more tox for triplet
🧐phs-3 terminated for futility, control arm outperformed, still a role for Triblet
@myESMO

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ESMO23 #crcsm
➡️ What is the benefit of EGFRi + triplet chemo in unresectable RASwt mCRC?
📌 PANIRINOX 🇫🇷 & TRICE 🇨🇳
- no ORR or PFS benefit seen with triplet over doublet
- c/w TRIPLETE 🇮🇹
📌 DEEPER 🇯🇵
- similar ORR with triplet EGFRvBev but depth of response better
My takeaways
➡️ when combined with EGFRi, a doublet remains SOC
➡️ when using a triplet, EGFRI vs Bev appear comparable. Consider toxicity!
@OncoAlert @myESMO

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ESMO23 #crcsm
🏅Presidential Session
📣CODEBREAK300 @FilippoPietran4
Ph3 sotorasib (960mg or 240mg)+pmab vs SOC in refractory #KRASG12C n=161 (2:1), mFU 7m
✅ mPFS @960mg 5.6m v 2.2m, HR 0.47
✅ ORR @960mg 26.4% v 0%
🔸 OS not mature
➡️ sotorasib 960mg + p’mab is a promising option in this biomarker selected pop’n #KRASG12C pre-treated mCRC 👏
🌟 Simultaneous @NEJM @myESMO @OncoAlert @mgfakih #precision #oncology

[Arndt Vogel @ArndtVogel]

Treatment of gastric adenocarcinoma: a rapidly evolving landscape
European Journal of Cancer
https://t.co/YyJtYzEVAR
👏great summary on this evolving field
👉More testing, more options for 🎯💊
@myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

Phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, + balstilimab (anti-PD-1) for heavily pretreated #mCRC at #WCGIC2023
👉deep & durable responses
👉higher efficacy in pts without liver mets
👉🌎randomized phase 2 (NCT05608044) ongoing
@WCGIC @myESMO @OncoAlert

[Breast Cancer Academy @BCancerAcademy]

On-line nuovi materiali!

📚Overall survival di olaparib nel trattamento adiuvante di pazienti affetti da carcinoma mammario in stadio precoce e mutazioni patogenetiche BRCA1-2
A cura di @CamillaLisanti

https://t.co/aa83LhmKCS

#breastcancer #cancer #cancers @BCancerAcademy

[ONcotwITting @ONcotwITting]

Le nuove frontiere della terapia anti-HER2: il potenziale degli anticorpi bispecifici https://t.co/ltir8CoGvy

[ONcotwITting @ONcotwITting]

Low & Order: bassa espressione di HER2 e nuove regole per il trattamento https://t.co/MqdKdtSIjo

[ONcotwITting @ONcotwITting]

Disegnato 20 anni fa ma più attuale che mai: è lo studio GIM2 https://t.co/I7a2rcm9iy

[ONcotwITting @ONcotwITting]

Si potrà omettere la chirurgia dopo una risposta patologica completa? https://t.co/SiF3linDLz

[ONcotwITting @ONcotwITting]

Terapia estrogenica vaginale e inibitori dell’aromatasi non sembrano andare d’accordo https://t.co/pghbEwUyPt

[Debora Basile @debora1090]

Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment https://t.co/EKXDaCdr7I

[Debora Basile @debora1090]

Deficient mismatch repair/microsatellite unstable colorectal cancer: D... https://t.co/qigdBgAbCF

[ONcotwITting @ONcotwITting]

Il trattamento del carcinoma mammario luminale metastatico: sguardo a Nord Est https://t.co/2NXaLLe62S

[ONcotwITting @ONcotwITting]

FAST, not furious https://t.co/dx8v8Z5hLl

[FabriceAndre @FAndreMD]

serum detection of tamoxifen: 16% non adherence at 1 year; associated with relapse. In this study, it s estimated that non-adherence could contribute to around 20% of relapses. A study from CANTO project by @BarbaraPistill2 and @inesvazluis https://t.co/bzzQO0DVXR